Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BDA MDI HFO 160/180 μg · 1 trial · 1 indication
To assess the equivalence of BDA MDI HFO relative to BDA MDI HFA on lung function in participants with asthma.
| Arm | Type | Description |
|---|---|---|
| BDA MDI HFO | ACTIVE_COMPARATOR | 160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFO |
| BDA MDI HFA | ACTIVE_COMPARATOR | 160/180 µg Budesonide/albuterol pressurized inhalation suspension, HFA |
| Placebo MDI HFA | PLACEBO_COMPARATOR | Placebo pressurized inhalation suspension, HFA |
| Name | Type | Description |
|---|---|---|
| BDA MDI HFO 160/180 μg | DRUG | Budesonide/albuterol pressurized inhalation suspension, HFO |
| BDA MDI HFA 160/180 μg | DRUG | Budesonide/albuterol pressurized inhalation suspension, HFA |
| Placebo MDI HFA | DRUG | Placebo pressurized inhalation suspension, HFA |
Inclusion Criteria: * Participant must be ≥ 18 years of age at the time of signing the ICF. * Participants who have physician diagnosed asthma as defined by GINA for at least 12 months prior to Visit 1. * Eligible participants are on either a) no daily inhaled maintenance therapy or b) daily inhale...
BDA MDI HFO 160/180 μg is an investigational small molecule being developed for the treatment of asthma. It is a metered-dose inhaler formulation of budesonide, a corticosteroid, using a next-generation propellant. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
BDA MDI HFO 160/180 μg contains budesonide, a corticosteroid that works by reducing inflammation in the airways. It is designed to be delivered via a metered-dose inhaler using a next-generation propellant. The drug is being studied for its effect on lung function in patients with asthma.
BDA MDI HFO 160/180 μg is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. The company is conducting a Phase 3 clinical trial to evaluate the drug's efficacy and safety in patients with asthma.
BDA MDI HFO 160/180 μg is currently in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The ongoing Phase 3 trial is active but not recruiting participants, with an enrollment of 422 patients.
BDA MDI HFO 160/180 μg is being studied in a Phase 3 clinical trial registered as NCT06502366. This randomized, double-blind, placebo-controlled trial is investigating the effect on lung function of BDA formulated with a next-generation propellant compared with an approved asthma treatment. The trial is active but not recruiting, with 422 participants.
BDA MDI HFO 160/180 μg is a formulation of budesonide, a corticosteroid used to treat asthma. It is delivered via a metered-dose inhaler using a next-generation propellant, which distinguishes it from other budesonide inhalers that use traditional propellants. The drug is being developed to potentially offer an alternative to existing treatments.